Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.

Zentiva’s Zent2U B2B unit says that it will be ready to register for a European generic version of Novartis’ Entresto immediately upon data exclusivity expiry, putting its version in position for a “day one” launch once intellectual property protecting the cardiovascular blockbuster expires.

Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.